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Multiple-Triazole–Resistant Aspergillosis 
To the Editor: The use of voriconazole has be-
come common for the management of invasive as-
pergillosis. However, therapy with voriconazole 
still sometimes fails, more often because of un-
responsive underlying disease than because of re-
sistance of the fungus. Since the first description 
of itraconazole resistance in Aspergillus fumigatus,1 
three amino acid substitutions in the 14α-sterol 
demethylase cyp51A gene, which is the target site 
for azole drugs, have been described.2
Our laboratory receives fungal isolates for iden-
tification and susceptibility testing from through-
out the Netherlands. Since 2002, using Clinical 
and Laboratory Standards Institute methodol-
ogy, we have observed an increase in the number 
of A. fumigatus isolates with elevated minimum 
inhibitory concentrations of voriconazole (2 to 
>16 mg per liter), itraconazole (>16 mg per liter), 
the investigational azole ravuconazole (4 to >16 mg 
per liter), and posaconazole (0.5 to 1.0 mg per 
liter). Thirteen isolates were cultured from nine 
patients from six hospitals in the Netherlands 
(Table 1). Primary aspergillosis was diagnosed 
in four patients, and five patients presented with 
breakthrough invasive aspergillosis.
A new mechanism of resistance, consisting of 
a Cyp51A amino acid substitution at codon 98 
(L98H) together with a tandem repeat in the gene 
promoter, was found to be responsible for the 
azole-resistant phenotype. This resistance mech-
anism was present in 12 of the 13 isolates. Ge-
notyping of the isolates showed no evidence for 
clonal spread of a single A. fumigatus genotype.
The prevalence of multiple-triazole resistance 
was compared with a previously conducted nation-
wide survey of 170 A. fumigatus isolates collected 
from 114 patients from 21 Dutch hospitals be-
tween 1945 and 1998.4 In this period, no patients 
with multiple-triazole–resistant isolates were found 
as compared with 10 of 81 patients in the period 
since 2002 (P<0.001).
Although the emergence of this new resistance 
mechanism coincides with the approval of vori-
conazole, the factors that may explain this phe-
nomenon remain unclear. Four patients became 
infected with a multiple-triazole–resistant strain 
during long-term prophylaxis with itraconazole, 
a drug that has been widely available for clinical 
use since 1991. The recovery of multiple-triazole–
resistant strains in patients who had not been 
previously treated with azoles suggests that alter-
native sources of azoles, such as the use of azole 
compounds in agricultural environments, might 
play a role.5
Our observation underscores the need to make 
an etiologic diagnosis of invasive mold infection 
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and to determine antifungal drug activity in clini-
cally relevant A. fumigatus isolates. Furthermore, 
international surveillance programs are warrant-
ed to investigate the spread of resistance in A. fu-
migatus.
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